The established safety profiles, dosing regimens, and manufacturing pathways of repurposed generics can significantly shorten timelines and reduce costs as alternative cancer therapies.
Ajoy Koppolu
Advertisement
Ajoy Koppolu, PhD, MBA; Pharmaceutical Industry Consultant, NJ 08823
Corresponding email: [email protected]
Articles by Ajoy Koppolu
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
2
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
3
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
4
A Pharma Manufacturing Blueprint from Delaware’s Innovation Vision
5